Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pollagen
- Development stage
- Phase 2
- Lead developer
- Danisco
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Pollagen is a probiotic combination developed by Danisco (now part of IFF) for the management of seasonal allergic rhinitis, specifically birch pollen allergy. It consists of two specific bacterial strains, *Lactobacillus acidophilus* NCFM (ATCC 700396) and *Bifidobacterium lactis* Bl-04 (ATCC SD5219), formulated in a 1:3 ratio (25% NCFM to 75% Bl-04). The product is designed to modulate the gut-immune axis, promoting Th1-type immune responses and downregulating Th2-mediated allergic inflammation. Clinical trials in children have demonstrated that pre-seasonal administration of this probiotic combination reduces nasal allergy symptoms and prevents the infiltration of eosinophils into the nasal mucosa during the birch pollen season. It is sometimes formulated as a synbiotic with the addition of fructo-oligosaccharides (FOS).
- Brand names
- PollagenPolagen
- Other names
- Lactobacillus acidophilus NCFM + Bifidobacterium lactis Bl-04L. acidophilus NCFM + B. lactis Bl-04
Beyond the preview
Go deeper on Pollagen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pollagen.